Atea Pharmaceuticals Inc.

Research activity includes COVID-19 in high-risk outpatients, with attention to reducing hospitalization and mortality in individuals receiving supportive care.

• Antiviral therapy
• Outpatient management
• Hospitalization prevention
• Mortality reduction

The sponsor’s clinical focus in this area centers on treatment options for symptomatic viral infection outside the hospital setting.